Close Menu

Pacific Biosciences

In a PrecisionFDA challenge, DeepVariant calls of PacBio HiFi reads topped 99 percent precision and recall for SNVs and indels, bringing HiFi in line with Illumina. 

The index underperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index, which all rose in August.

The sequencing firm is offering 19.4 million shares of common stock at $4.47 per share and plans to use the proceeds for product launches, among other uses.

The sequencing firm said the COVID-19 pandemic had a negative impact on revenues, which totaled $17.1 million, down from $24.6 million in the prior-year period.

Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.

The index outperformed the Dow Jones, the Nasdaq, and the Nasdaq Biotechnology Index in the first half of the year.

The public-private partnership has published a paper on a list of indels larger than 50 bp that is already being used to develop new methods.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.